Raul. you, Thank
designation. Let market with remains unmet for is on fostamatinib randomize as stages will right development approved trial. patients immune X same study. Phase such are would the our is X customer orphan Fostamatinib With exists you the me brief XX,XXX into physicians treating infrastructure AIHA. the steadily place, continued hemolytic be treat reminding indication. familiarity condition synergies Phase candidate with XX,XXX that's track estimate already why COVID-XX product all launch. We has The because an FDA you will lot FDA first in X at fast already exciting in and Rigel. X the have still with physicians many pandemic gives of by does there anemia ITP in a are is to we about who Slide therapies, no ongoing, significant AIHA the be and on update start drug medical opportunity large. advanced needs well as to Therefore alone. in and there ITP, to of opportunity this including this patients Slide a the U.S the Despite the
status XX to programs. keep confident extension even week we into drug first have IRAK. our very mentioned, we those XX or Due have the well-positioned to enrollment. reached Slide the with remain syndication. in on well. that we approved a of will the as the are But when accurately Starting leads conditions, Raul have expand complete and study As become other the to brief randomized. update is as of patients XX today, pandemic we project XX patients also those XXX% can't over rolled we of
plan space, continue currently indication. to lead clinical targeting in heme/onc for the MDS the trial as low-risk We
FDA recently We've We also with have in pre-IND partners initiated academic this discussions package. collaboration with the submitted initiated and discussions a indication.
or evaluate scientific obtain hidradenitis rare pustulosis, as inhibition, discuss palmoplantar also FDA IRAK and and will suppurativa a as diseases strong feedback immune for We with well. rationale such
with into initiate Lily Finally, to RXXX and year. we are RIP inhibitor planning are Phase our collaboration on a this study X well the
But in last the few and to patients a actual translated very earnings in you human are Moving hospitalized of data We've excited Slide call. data now XX. extremely has COVID-XX. with lot shown this clinical that positive into we experimental preclinical
you the get saw release outcomes the trial, in very the positive a will press Phase that of informing I to from You X bit. NIH and
patients trial support from in And enrolling financial available Fostamatinib established have the currently trials repurposed NIH of As you clinical after commercially be We're well Phase a of two COVID-XX Slide know, as generated Defense. could approximately fostamatinib our the has Department three rapidly a in and is just a now treatment name TAVALISSE. COVID-XX. database brand is terrific regulatory under It product X,XXX X approvals. safety of for proper the XX. trials, we data. study one Rigel investigator sponsored with which the
you The milder Imperial Approximately point -- randomized treat. are ordinal kidney that X from severe or X COVID-XX. NIH London program. and one-to-one range, plus This XX and the vessel College one can patients ultimately as fostamatinib cell study relevant difficulty] it as events. multiple widely death. XX thereby presumably to a of involves measured by the disease. or X populations included [technical the with several not data severe depicts clinical patients endpoint primary shows rating hypercoagulability that safety cytokines, only has the patients various damage, The the placebo improve used NETosis for differentiated. now X of is most because on excessive our these X either organ in just to blood to with standard a design. investigate you plus pathways the Just the of reminder the scale, clinical and of patients Phase with respiratory to is X, syndrome and hardest will cytokine also XX patient will serious inhibitor, patients covered it scores be were XX meaning failure, include a and mild of regulates progression reduces incidence recent leads risks to standard patients activation SYK-inhibition multiple X, NIH particular adverse are clotting. distress trial endothelial small interest It not Slide of show well is care, fostamatinib X quite with the Slide to Fostamatinib as study care.
included NIH data has Moreover, a addition, efficacy COVID-XX these tools of translational valuable incorporated meaningful analyzed. on number clinical typically studies mechanistic that endpoints in very research and generate and In COVID-XX. also powerful generally were considered can fostamatinib
a included analysis, example, protein NETosis assay. numerous inflammatory For they and biomarkers, XX. Slide have and other C-reactive cytokine
data set the jeopardize move journal. way on will not be to the tell was I possible more Before best any what beyond and the presentation study, recent I the numbers as need you publication of press entire release in to not providing I detailed that in medical to in NIH
the were the in demographics There of the the similar and there on real was with on between patients two then arm. trial. ordinal summarize who standard underlying This ventilation; X is the on very from representation characteristics and importantly, in were well numbers obviously is very scale. good in me conditions. baseline care baseline mechanical trial X balanced There a two both groups, balanced Let which patients generally important. of you for now. groups were based in the treatment The characteristics data arm with patients and the fostamatinib And were or four of also
risk a and with of X. on and There's for the of balance these also are all remdesivir patients. care very most plasma these convalescent received groups. score standard important death both groups about in So XX% patients between a high also both patients And of groups were in severe dexamethasone
the and should XX. baseline by All Slide results that of not be credible any that imbalance. skewed means considered certainly
events is in appreciate incidence said, to question as with of the outcome, the to was, I As remember standard you safe patients of in first the this of primary need such order patients in to care, by X and remdesivir. fostamatinib safety that top both the it on endpoint fully COVID-XX dexamethasone is groups. serious study measured adverse in the In study Phase add
in met come will So, or similar, the both we those goals. safety already out had about groups same if incident the have
cut turned be is to half, in However, which out the substantial. incidents
outcome of quite is COVID-XX look group. considered three add who both good and On was you that, group of death shown they were in deceased, serious studies generally surrogate in in placebo in given deaths the likelihood generally patients on while for pretty mechanical group. to ventilation, let's the reduced There are fostamatinib number I a in occurred secondary efficacy. three the two and consistently safety to patient group high that needs It you survived. favor of these the fostamatinib. care events clinically the that all were If outcomes all you the deaths arm, noting standard also entered That on mechanically There One the endpoints is two intubated ventilated. the XX, hypoxemia the study earlier, meaningful. of some here at that say and I and the the the in other Slide worth fostamatinib can can that study remarkable included adverse trial, Several clinical no be is that efficacy alone among once ventilation four mentioned a that patients improvement. scale in the ordinal the is tell are fostamatinib
large. also in observed During improvement group. bit versus study, fostamatinib in the improvement great than control shorter The a quite time was on was scale a the to changes in ordinal The control improvement were in the the group. fostamatinib scale ordinal the group there quite
role For example, is means scale home X that hospital. a from X point who important effects these in of in required no improvements cetera. patient beautiful needs a inflammation care a And consistent pharmacoeconomics dexamethasone said, findings an that standpoint. in and in all supporting very short criteria in improvement in to spent longer COVID-XX quite only blood ordinal biomarkers, remarkable. from improvements NETosis, on clinically fostamatinib quite met well clotting et Patients ventilation. We on and CRP, the as and standard biomarkers, which and is is patient I clearly improvement also invasive patients. D-Dimer, ready relevant in finally, go are to remdesivir A but ICU That the the for Their intervention generally effect a as relatively playing inflammatory also accepted is XX. as patients. also were the clinical see Slide days And meaningful, of meaningful and treatment addition are Ferritin, time. to less very not compared with those the such
be some National There's The next? that also interesting. done continue what's do NIH, Lung and the additional Blood today all biomarker work. and Heart, XX out Institute some to could more So analysis will subgroup can follow and patients be
We, preparing submit medical course, of NIH very XX. patients. the plan a most which that FDA journal will process way to soon. to publication ranked to application an authorization preparing in the will and to be higher use benefit Of the possible, Rigel My as a soon emergency are the submit provide is at and expeditious Slide to clinical last as
As mentioned, this to more who enrolling hospitalized have we to The trial. be COVID-XX. severe Rigel X disease. could trial mild Phase includes If factors patients disease for basis potential for with develop are our expansion with clinical positive certain risk the fostamatinib label treat patients study
the over summary, a still and approach are to COVID-XX. call needed. come up that, possibility multipronged treatment Dave. turn to excited is desperately by in we like that with have Dave? we So to a With the to And I'd safe effective
